Research biobanks are heterogeneous and exist to manage diverse biosample types with the goal of facilitating and serving biomedical discovery. The perspectives of biobank managers are reviewed, and the perspectives of two biobank directors, one with experience in institutional biobanks and the other with national cooperative group banks, are presented. Most research biobanks are not designed, nor do they have the resources, to return research results and incidental findings to participants or their families.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617601 | PMC |
| http://dx.doi.org/10.1111/jlme.12294 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human iPSC Reprogramming Success: The Impact of Approaches and Source Materials.
Stem Cells Int
January 2025
Biobanking Department, Coriell Institute for Medical Research, Camden 08003, New Jersey, USA.
Since their discovery, human induced pluripotent stem cells (hiPSCs) have been instrumental in biomedical research, particularly in the fields of disease modelling, drug screening and regenerative therapies. Their use has significantly increased over recent years driven by the ability of hiPSCs to provide differentiated cell models without requiring embryonic stem cells. Furthermore, the transition from integrating to non-integrating reprogramming methodologies has contributed to the increase in utilisation.
View Article and Find Full Text PDFThe hidden impact: social isolation and inflammation's role in pancreatic cancer risk among those with diabetes.
BMC Cancer
January 2025
Department of Epidemiology and Health Statistics, School of Public Health, Hangzhou Medical College, 481 Binwen Road, Hangzhou, 310053, China.
Background: Pancreatic cancer poses a significant challenge in individuals with diabetes, prompting a reevaluation of established risk factors beyond conventional glycemic control measures.
Objectives: To explore the complex interplay of metabolic and psychosocial determinants in pancreatic cancer risk among individuals with diabetes, challenging prevailing perspectives and advocating for a comprehensive approach.
Methods: A total of 21,945 UK Biobank participants with baseline diabetes diagnosis were analyzed.
Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study.
Diabetes Obes Metab
January 2025
Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Major Diseases in the Population, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Background: Fatty liver disease may be associated with increased risks of intrahepatic and extrahepatic cancers. Our objective was to investigate associations between new subcategories of steatotic liver disease (SLD) recently proposed by nomenclature consensus group and cancer risk.
Methods: A total of 283 238 participants from the UK Biobank were included.
Toward a More General Consent for the Use of Patients' Biological Material and Health Information for Medical Research-The Patient Perspective.
Biopreserv Biobank
January 2025
Department for Food Safety, Norwegian Institute of Public Health, Oslo, Norway.
Biological material and health information from patients are valuable for medical research. Under a "broad" consent model, hospital patients in Norway can consent to their biological material and health information being stored in research biobanks and used for "specific, broadly defined research purposes" within a specified medical research area but not for medical research in general. Patients are asked to provide new consent each time researchers wish to use their material in a different medical research area.
View Article and Find Full Text PDFSimplifying coronary artery disease risk stratification: development and validation of a questionnaire-based alternative comparable to clinical risk tools.
EBioMedicine
January 2025
Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Background: Coronary artery disease (CAD) comprises one of the leading causes of morbidity and mortality both in the European population and globally. All established clinical risk stratification scores and models require blood lipids and physical measurements. The latest reports of the European Commission suggest that attracting health professionals to collect these data can be challenging, both from a logistic and cost perspective, which limits the usefulness of established models and makes them unsuitable for population-wide screening in resource-limited settings, i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!